Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab hyperthermic intraperitoneal perfusion combined with sintilimab for malignant ascites
ChiCTR2200060643Phase 2Recruiting
- Sponsor
- Sichuan University West China Hospital
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and sintilimab in malignant ascites, sponsored by Sichuan University West China Hospital. Primary endpoint: objective response rate. Started Mar 2022; status: recruiting.
02
Drugs
bevacizumabsintilimab
03
Conditions
malignant ascites
Beyond the preview
Go deeper on ChiCTR2200060643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060643.